https://www.nasdaq.com/press-release/data-on-gencaro-impact-on-prevention-of-bradycardia-published-in-heart-rhythm-o2-2022
https://www.nasdaq.com/press-release/arca-biopharma-announces-completion-of-enrollment-in-phase-2b-aspen-covid-19-clinical
https://www.nasdaq.com/press-release/arca-biopharma-to-present-at-the-q4-virtual-investor-summit-on-november-17th-2021-11
https://www.nasdaq.com/press-release/arca-biopharma-announces-third-quarter-2021-financial-results-and-provides-corporate
https://www.nasdaq.com/press-release/aspen-covid-19-data-and-safety-monitoring-committee-recommends-continuing-phase-2b
https://www.nasdaq.com/press-release/arca-biopharma-announces-enrollment-of-first-international-patient-in-phase-2b
https://www.nasdaq.com/press-release/arca-biopharma-to-present-at-the-q3-virtual-investor-summit-on-august-18th-2021-08-16
https://www.nasdaq.com/press-release/arca-biopharma-announces-submission-of-pct-patent-application-for-the-treatment-of
https://www.nasdaq.com/press-release/arca-biopharma-announces-second-quarter-2021-financial-results-and-provides-corporate
https://www.nasdaq.com/press-release/gencaro-atrial-fibrillation-phase-2b-results-selected-for-publication-in-circulation%3a
https://www.nasdaq.com/press-release/arca-biopharma-provides-update-on-aspen-covid-19-phase-2b-clinical-trial-evaluating
https://www.nasdaq.com/press-release/arca-biopharma-to-present-at-access-to-giving-virtual-investor-conference-on-july
https://www.nasdaq.com/press-release/50-companies-to-present-at-the-access-to-giving-virtual-investor-conference-on-july-0
https://www.nasdaq.com/press-release/arca-biopharma-announces-rnapc2-covid-19-patent-assignment-agreement-2021-07-07
https://www.nasdaq.com/press-release/50-companies-to-present-at-the-access-to-giving-virtual-investor-conference-on-july
https://www.nasdaq.com/press-release/arca-biopharma-announces-first-quarter-2021-financial-results-and-provides-corporate
https://www.nasdaq.com/press-release/christopher-graybill-joins-arca-as-vice-president-clinical-development-2021-05-05
https://www.nasdaq.com/press-release/arca-biopharma-announces-c.-jeff-dekker-to-be-appointed-chief-financial-officer-2021
https://www.nasdaq.com/press-release/arca-biopharma-announces-2020-financial-results-and-provides-corporate-update-2021-03
https://www.nasdaq.com/press-release/arca-biopharma-announces-first-patients-enrolled-in-aspen-covid-19-phase-2b-clinical
https://www.nasdaq.com/press-release/arca-biopharma-announces-location-change-for-2020-annual-meeting-of-stockholders-2020
https://www.nasdaq.com/press-release/ab201-development-as-a-potential-treatment-for-covid-19-receives-u.s.-fda-fast-track
https://www.nasdaq.com/press-release/arca-biopharma-announces-third-quarter-2020-financial-results-and-provides-corporate
https://www.nasdaq.com/press-release/arca-biopharma-announces-fda-approval-of-ind-application-for-ab201-as-a-potential
https://www.nasdaq.com/press-release/arca-biopharma-announces-promotion-of-chief-medical-officer-and-vice-president
https://www.nasdaq.com/press-release/arca-biopharma-announces-submission-of-ind-application-to-u.s.-fda-for-ab201-as-a
https://www.nasdaq.com/press-release/arca-biopharma-announces-completion-of-fda-pre-ind-consultation-under-coronavirus
https://www.nasdaq.com/press-release/arca-biopharma-announces-second-quarter-2020-financial-results-and-provides-corporate
https://www.nasdaq.com/press-release/sars-cov-2-cell-entry-mechanisms-in-intact-human-heart-published-in-jacc%3a-basic-to
https://www.nasdaq.com/press-release/arca-biopharma-announces-closing-of-%246.1-million-registered-direct-offering-2020-06
https://www.nasdaq.com/press-release/arca-biopharma-announces-%249.4-million-registered-direct-offering-2020-06-01
https://www.nasdaq.com/press-release/arca-biopharma-announces-ab201-development-program-for-treatment-of-covid-19
https://www.nasdaq.com/press-release/clinical-data-evaluating-gencaro-for-the-treatment-of-atrial-fibrillation-in-heart
https://www.nasdaq.com/press-release/arca-biopharma-announces-first-quarter-2020-financial-results-and-provides-corporate
https://www.nasdaq.com/press-release/arca-biopharma-announces-fiscal-year-2019-financial-results-and-provides-corporate
https://www.nasdaq.com/press-release/arca-biopharma-announces-third-quarter-2019-financial-results-and-provides-corporate
